Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa A de Jong

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Cancer Treatment and Research Communications|September 18, 2025
Trends in breast cancer in Indonesia from 2017 to 2020: A national-level analysis by age and disease severitySudewi Mukaromah Khoirunnisa, Didik Setiawan, Maarten J Postma, et al.
Clinical Therapeutics|February 1, 2017
Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the NetherlandsLisa A de Jong, Evgeni Dvortsin, Kristel J Janssen, et al.
Pharmacoeconomics - Open|September 20, 2019
Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The NetherlandsJudith J Gout-Zwart, Lisa A de Jong, Lisanne Saptenno, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|September 25, 2023
Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies - can alignment be improved?Sharon Wolters, Lisa A de Jong, Christel Jansen, et al.
BMJ Open|January 14, 2021
Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolismLisa A de Jong, Annette W G van der Velden, Marinus van Hulst, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|November 29, 2017
Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillationMaartje S Jacobs, Lisa A de Jong, Maarten J Postma, et al.
Journal of Medical Internet Research|September 26, 2023
The Use of eHealth for Pharmacotherapy Management With Patients With Respiratory Disease, Cardiovascular Disease, or Diabetes: Scoping ReviewRobbert Bakema, Daria Smirnova, Despina Biri, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 12, 2020
Author's ReplySimon van der Pol, Lisa A de Jong, Pepijn Vemer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 30, 2019
Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency FrontierSimon van der Pol, Lisa A de Jong, Pepijn Vemer, et al.
Plos One|February 27, 2025
Early economic evaluation of chelation therapy in kidney transplant recipients with high-normal leadJiasi Hao, Behrooz Z Alizadeh, Maarten J Postma, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Cancer Treatment and Research Communications|September 18, 2025
Trends in breast cancer in Indonesia from 2017 to 2020: A national-level analysis by age and disease severitySudewi Mukaromah Khoirunnisa, Didik Setiawan, Maarten J Postma, et al.
Clinical Therapeutics|February 1, 2017
Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the NetherlandsLisa A de Jong, Evgeni Dvortsin, Kristel J Janssen, et al.
Pharmacoeconomics - Open|September 20, 2019
Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The NetherlandsJudith J Gout-Zwart, Lisa A de Jong, Lisanne Saptenno, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|September 25, 2023
Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies - can alignment be improved?Sharon Wolters, Lisa A de Jong, Christel Jansen, et al.
BMJ Open|January 14, 2021
Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolismLisa A de Jong, Annette W G van der Velden, Marinus van Hulst, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|November 29, 2017
Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillationMaartje S Jacobs, Lisa A de Jong, Maarten J Postma, et al.
Journal of Medical Internet Research|September 26, 2023
The Use of eHealth for Pharmacotherapy Management With Patients With Respiratory Disease, Cardiovascular Disease, or Diabetes: Scoping ReviewRobbert Bakema, Daria Smirnova, Despina Biri, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 12, 2020
Author's ReplySimon van der Pol, Lisa A de Jong, Pepijn Vemer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 30, 2019
Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency FrontierSimon van der Pol, Lisa A de Jong, Pepijn Vemer, et al.
Plos One|February 27, 2025
Early economic evaluation of chelation therapy in kidney transplant recipients with high-normal leadJiasi Hao, Behrooz Z Alizadeh, Maarten J Postma, et al.
Pageof 2